The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

Why would Trump be OK with forcing Americans to pay more than the rest of the world for their drugs? The answer is simple: ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...